Rheumatoid arthritis
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
Health Technology Assessment. 2011;15(14):1-278
Authors
Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF
Process
A
B
C
Publications in other disease areas
Atrial fibrillation
Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke
Cancer
Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom
Idiopathic pulmonary fibrosis
The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review
Psoriasis
The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis
Rheumatoid arthritis
Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK
Venous thromboembolism
Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective